Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10506317 | 0.80 | SMN1; SMN2 (0.60) | LMNAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL7595572 | 0.79 | PDK2 (0.58) | PDK2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL14327977 | 0.76 | L3MBTL1 (0.64) | LMNAARALDH1A1MEN1KMT2A | |
| SCHEMBL15391794 | 0.75 | SMN1; SMN2 (0.70) | LMNAALDH1A1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL4762266 | 0.75 | KDM4E (0.37) | PDK2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL3783343 | 0.74 | ALDH1A1 (0.58) | LMNAALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL2904007 | 0.74 | NOTUM (0.61) | LMNAALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL5317080 | 0.74 | L3MBTL1 (0.68) | LMNAALDH1A1MAPTMCL1CYP1A2 | |
| SCHEMBL6243487 | 0.74 | GAA (0.57) | LMNAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL14191206 | 0.73 | CA1 (0.50) | PDK2LMNAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020052354-A1 | Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction | SCHERING AG | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052354-A1 | Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction | TNNI3, NPR1, LPXN | PDK2 653/4885LMNA 14/4885DDB1 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.